• 2016 Citations
  • 18 h-Index
20032020

Research output per year

If you made any changes in Pure these will be visible here soon.

Personal profile

Personal profile

Dr. Zeenat Safdar is an Associate Professor of Medicine, Houston Methodist Academic Institute, and Director of Clinical Research and Pulmonary Hypertension Program, Houston Methodist Hospital Lung Center in Houston, Texas. She is also an Adjunct Associate Professor of Medicine at Baylor College of Medicine.

Dr. Safdar serves as a Chair of Young Council at Pulmonary Vascular Research Institute, Pulmonology Chair at the Pulmonary Hypertension Association Online University, and National Chair at PHA on the Road program. She serves as Registries and Databases Workforce leader at PH council of International Society of Heart Lung Transplantation (ISHLT).

Dr. Safdar is a Fellow of the American College of Physicians, American College of Chest Physicians (CHEST), and Pulmonary Vascular Research Institute. She is a member of the PH Council of International Society of Heart Lung Transplant, American Thoracic Society and Texas Medical Association.

She has been invited to serve as the session facilitator, presenter, and abstract reviewer and selector at the International Conference of the ATS, CHEST and ISHLT. Dr. Safdar has served as an invited reviewer for the American Journal of Respiratory and Critical Care Medicine, Respiratory Medicine and Therapeutic Advances in Respiratory Disease and serves as a member of the editorial board of several journals.

Research interests

Dr. Safdar’s principal area of interest is Pulmonary Arterial Hypertension (PAH), specifically translational research, clinical research and clinical trials. Her recent research has focused on the contribution of renin-angiotensin-aldosterone system to the pathophysiology of PAH. She is the principal and co-investigator of several ongoing clinical trials including

  • REATA - a phase 2 dose-ranging study of efficacy and safety of Bardoxolone Methyl in PAH
  • LIBERTY - a phase 2 study of Ubenimex in patient with PAH
  • TRANSIT-1 - a study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in PAH
  • Chronic ThromboEmbolic Pulmonary Hypertension registry
  • TRITON - The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed PAH
  • RIN-PH - Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

 The Houston Methodist Hospital Pulmonary Hypertension program also provides expert care for patients with idiopathic pulmonary fibrosis (IPF). As a Director of the IPF program, she serves as a lead investigator of several ongoing IPF clinical trials including 

  • RIFF study - a phase 2 randomized placebo-controlled clinical study to assess the safety and efficacy of Lebrikizumab in IPF
  • RAINIER study - a phase 2 multicenter study to assess the efficacy and safety of Simtuzamab in IPF

 She was the site investigator of several complete IPF clinical trials such as

  • ARTEMIS-IPF - ambrisentan for IPF
  • ARTEMIS-PH - ambrisentan in PH associated with IPF
  • MUSIC - macitentan for IPF

 Dr. Safdar is the recipient of a K23 grant from the National Institute of Health (NIH) and several other grants from non-profit organizations.  Her research has been published in prominent, high impact journals.

Research Area Keywords

  • Clinical Translation & Trials
  • Clinical Care

Free-text keywords

  • Pulmonary Arterial Hypertension (PAH)
  • Idiopathic Pulmonary Fibrosis (IPF)
  • Pulmonary disease

Fingerprint Dive into the research topics where Zeenat Safdar is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 3 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects

Research Output

Ambrisentan in portopulmonary hypertension: A multicenter, open-label trial

Preston, I. R., Burger, C. D., Bartolome, S., Safdar, Z., Krowka, M., Sood, N., Ford, H. J., Battarjee, W. F., Chakinala, M. M., Gomberg-Maitland, M. & Hill, N. S., May 1 2020, In : Journal of Heart and Lung Transplantation. 39, 5, p. 464-472 9 p.

Research output: Contribution to journalArticle

  • Circulating matrix metalloproteinases and tissue metalloproteinase inhibitors in patients with idiopathic pulmonary fibrosis in the multicenter IPF-PRO Registry cohort

    Todd, J. L., Vinisko, R., Liu, Y., Neely, M. L., Overton, R., Flaherty, K. R., Noth, I., Newby, L. K., Lasky, J. A., Olman, M. A., Hesslinger, C., Leonard, T. B., Palmer, S. M., Belperio, J. A., Asi, W., Baker, A., Beegle, S., Condos, R., Cordova, F., Culver, D. A. & 34 others, Luckhardt, T., Dilling, D., Glassberg, M., Gulati, M., Guntupalli, K., Gupta, N., Hotchkin, D., Huie, T., Kaner, R., Kim, H., Kreider, M., Lancaster, L., Lederer, D., Lee, D., Liesching, T., Lipchik, R., Lobo, J., Mageto, Y., Menon, P., Morrison, L., Namen, A., Oldham, J., Raj, R., Ramaswamy, M., Russell, T., Sachs, P., Safdar, Z., Sigal, B., Silhan, L., Strek, M., Suliman, S., Tabak, J., Walia, R. & Whelan, T. P., Mar 14 2020, In : BMC Pulmonary Medicine. 20, 1, 64.

    Research output: Contribution to journalArticle

  • Disease Severity and Quality of Life in Patients With Idiopathic Pulmonary Fibrosis: A Cross-Sectional Analysis of the IPF-PRO Registry

    IPF-PRO Registry investigators, May 2020, In : CHEST. 157, 5, p. 1188-1198 11 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations

    Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: A Delphi consensus study

    Rahaghi, F. F., Safdar, Z., Brown, A. W., De Andrade, J. A., Flaherty, K. R., Kaner, R. J., King, C. S., Padilla, M. L., Noth, I., Scholand, M. B., Shifren, A. & Nathan, S. D., Jul 14 2020, In : BMC Pulmonary Medicine. 20, 1, 191.

    Research output: Contribution to journalArticle

    Open Access